Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matejka Rebolj

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Scandinavian Journal of Public Health|July 22, 2011
The Danish National Patient RegisterElsebeth Lynge, Jakob Lynge Sandegaard, Matejka Rebolj
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|October 5, 2011
Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30: systematic reviewMatejka Rebolj, Sisse H Njor, Elsebeth Lynge
Acta Oncologica (Stockholm, Sweden)|February 12, 2014
Trends of cervical cancer in Greenland: a 60-year overviewBente B Sander, Matejka Rebolj, Elsebeth Lynge
British Journal of Cancer|April 13, 2024
Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screeningMatejka Rebolj, Adam R Brentnall, Kate Cuschieri
British Journal of Cancer|February 9, 2021
Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnosesAlejandra Castanon, Matejka Rebolj, Francesca Pesola, et al.
Scandinavian Journal of Public Health|July 22, 2011
Register-based studies of cancer screening effectsMy Von Euler-Chelpin, Elsebeth Lynge, Matejka Rebolj
Obstetrics and Gynecology|August 5, 2021
Human Papillomavirus Testing in the Last Cervical Screening Round at Age 60-64 YearsJeppe Bennekou Schroll, Reza Rafiolsadat Serizawa, Matejka Rebolj
Preventive Medicine|December 29, 2022
Concurrent participation in breast, cervical, and colorectal cancer screening programmes in Denmark: A nationwide registry-based studySisse Helle Njor, Bo Søborg, Mette Tranberg, et al.
Expert Review of Anticancer Therapy|December 25, 2012
Immunosuppression and risk of cervical cancerPierre-Antoine Dugué, Matejka Rebolj, Peter Garred, et al.
BMJ (Clinical Research Ed.)|May 25, 2011
Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic reviewMatejka Rebolj, Jesper Bonde, Sisse Helle Njor, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Scandinavian Journal of Public Health|July 22, 2011
The Danish National Patient RegisterElsebeth Lynge, Jakob Lynge Sandegaard, Matejka Rebolj
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|October 5, 2011
Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30: systematic reviewMatejka Rebolj, Sisse H Njor, Elsebeth Lynge
Acta Oncologica (Stockholm, Sweden)|February 12, 2014
Trends of cervical cancer in Greenland: a 60-year overviewBente B Sander, Matejka Rebolj, Elsebeth Lynge
British Journal of Cancer|April 13, 2024
Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screeningMatejka Rebolj, Adam R Brentnall, Kate Cuschieri
British Journal of Cancer|February 9, 2021
Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnosesAlejandra Castanon, Matejka Rebolj, Francesca Pesola, et al.
Scandinavian Journal of Public Health|July 22, 2011
Register-based studies of cancer screening effectsMy Von Euler-Chelpin, Elsebeth Lynge, Matejka Rebolj
Obstetrics and Gynecology|August 5, 2021
Human Papillomavirus Testing in the Last Cervical Screening Round at Age 60-64 YearsJeppe Bennekou Schroll, Reza Rafiolsadat Serizawa, Matejka Rebolj
Preventive Medicine|December 29, 2022
Concurrent participation in breast, cervical, and colorectal cancer screening programmes in Denmark: A nationwide registry-based studySisse Helle Njor, Bo Søborg, Mette Tranberg, et al.
Expert Review of Anticancer Therapy|December 25, 2012
Immunosuppression and risk of cervical cancerPierre-Antoine Dugué, Matejka Rebolj, Peter Garred, et al.
BMJ (Clinical Research Ed.)|May 25, 2011
Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic reviewMatejka Rebolj, Jesper Bonde, Sisse Helle Njor, et al.
Pageof 9